Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
GeoVax Labs Inc
GOVX
Healthcare
Biotechnology
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include...
preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GOVX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(305)
•••
whytestocks
X
Post by
whytestocks
on Mar 08, 2024 1:00pm
GeoVax Labs, Inc. (NASDAQ: GOVX) Featured in Coverage of the
News; $GOVX GeoVax Labs, Inc. (NASDAQ: GOVX) Featured in Coverage of the 36th Annual Roth ConferenceGeoVax Labs (NASDAQ: GOVX) , is a clinical-stage biotech company committed to developing safe and
...more
(28)
•••
thedave2006
X
Post by
thedave2006
on Aug 05, 2022 7:25am
monkeypox play
.
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 20, 2021 8:17am
GOVX ..... Here's one I should have kept
U know what they say about "hindsight" Made some lunch money. Cheers !
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 19, 2021 11:51am
GOVX .....scalped
Thanks for the dough !
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 19, 2021 11:23am
GOVX
WO2021163622 VACCINES AND USES THEREOF TO INDUCE AN IMMUNE RESPONSE TO SARS-COV2 (wipo.int)
(1)
•••
Red~One
X
Post by
Red~One
on Jan 11, 2021 9:23am
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Develop
GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development Email Print Friendly Share January 11, 2021 09:00 ET | Source: GeoVax, Inc
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Eminent's First Drill Hole Hits Significant Gold-Arsenic in Getchell Trend Analogue and Second Hole Drilling Commences
U.S. DOD Logistics Agency Highlights V.GPH Project to Develop Eco-Friendly Graphite-Based Fire-Fighting Material
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.
Alphamin Announces Record Fy2024 & Q4 2024 Tin Production Fy2025 Production Guidance Exploration Success
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*